Tumor angiogenesis of non-small cell lung cancer

Microscopy Research and Technique

Volumn 60, Issue 2, 2003, Pages 186-198

  Shijubo, Noriharu ^a   Kojima, Hiroshi ^a   Nagata, Manabu ^a   Ohchi, Takashi ^a   Suzuki, Akihiro ^a   Abe, Shosaku ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

bFGF; Chemokine; Integrin; Mast cells; MMP; Osteopontin; PD ECGF; VE cadherin; VEGF

Indexed keywords

ADHESION; BIOLOGICAL ORGANS; CELL CULTURE; DIAGNOSIS; DISEASES; FIBROBLASTS; GLYCOPROTEINS; MOLECULES; TUMORS;

BFGF; CHEMOKINES; INTEGRINS; MAST CELLS; MMP; NON SMALL CELL LUNG CANCER; OSTEOPONTIN; PD-ECGF; VE-CADHERIN; VEGF;

ENDOTHELIAL CELLS;

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; CADHERIN; CD31 ANTIGEN; CHYMASE; ENDOSTATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PLASMINOGEN ACTIVATOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROLACTIN; SELECTIN; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MACROPHAGE; MAST CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0037303745     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10257     Document Type: Review

References (235)

1. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548-553.
2. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. 2001. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276:28261-28267.
3. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A, Kondo T, Tanita T, Matsumura Y, Ono S, Saito Y, Sagawa M. 1999. Immunohistochemical study on tumor angiogenic factors in nonsmall cell lung cancer. Anticancer Res 19:4305-4309.
4. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155-162.
5. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. 1996. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97:2792-2802.
6. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM. 1997. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 62:554-562.
7. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM. 1998. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 102:465-472.
8. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. 1995. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92S:II365-II371.
9. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864.
10. Bayless KJ, Meininger GA, Scholtz JM, Davis GE 1998 Osteopontin is a ligand for the α4β1 integrin. J Cell Sci 111:1165-1174.
11. Becker D, Meier CB, Herlyn M. 1989. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 8:3685-3691.
12. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL. 1997. Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. J Clin Invest 99:2691-2700.
13. Blei F, Wilson EL, Mignatti P, Rifkin DB. 1993. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155:568-578.
14. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, Galli SJ. 1998. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med 188:1135-1145.
15. Breier G, Breviario F, Caveda L, Berthier R, Schnurch H, Gotsch U, Vestweber D, Risau W, Dejana E. 1996. Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 87:630-641.
16. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. 1993a. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735.
17. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. 1993b. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262.
18. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. 1993c. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574-578.
19. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. 1995. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91.
20. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S, Ohno S. 1996. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639-649.
21. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC, Mantovani A. 1991. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 87:986-995.
22. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-257.
23. Casson AG, Wilson SM, McCart JA, O'Malley FP, Ozcelik H, Tsao MS, Chambers AF. 1997. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 72:739-745.
24. Chambers, AF. Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. 1996. Osteopontin expression in lung cancer. Lung Cancer 15:311-323.
25. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ, 1996, Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-741.
26. Cox G, Steward WP, O'Byrne KJ. 1999. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 54:169-179.
27. Cox G, Jones JL, Walker RA, Steward WP, O'Byrne KJ. 2000a Angiogenesis and non-small cell lung cancer. Lung Cancer 27:81-100.
28. Cox G, Jones JL, O'Byrne KJ. 2000b. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6:2349-2355.
29. Cozzolino F, Torcia M, Lucibello M, Morbidelli L, Ziche M, Platt J, Fabiani S, Brett J, Stern D. 1993. Interferon-α and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 91:2504-2512.
30. Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, Eidsvoog K. 1994. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 55:277-284.
31. Czubayko F, Smith RV, Chung HC, Wellstein A. 1994. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269:28243-28248.
32. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. 1997. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3:1137-1140.
33. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. 1996. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169.
34. DeLisser HM, Newman PJ, Albelda SM. 1994. Molecular and functional aspects of PECAM-1/CD31. Immunol Today 15:490-495.
35. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. 1997. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671-677.
36. Dembinska-Kiec A, Dulak J, Partyka L, Huk I, Mailnski T. 1997. VEGF-nitric oxide reciprocal regulation. Nat Med 3:1177.
37. Denda S, Reichardt LF, Muller U. 1998. Identification of osteopontin as a novel ligand for the integrin α8β1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell 19:1425-1435.
38. Denhardt DT, Gou X. 1993. Osteopontin: a protein with diverse functions. FASEB J 7:1475-1482.
39. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM. 1997. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 57:5590-5597.
40. Devoll RE, Li W, Woods KV, Pinero GJ, Butler WT, Farach-Carson MC, Happonen RP. 1999. Osteopontin (OPN) distribution in pre-malignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 28:97-101.
41. Dimitiradou V, Koutsilieris M. 1997. Mast cell-tumor interactions: for or against tumour growth and metastasis. Anticancer Res 17:1541-1549.
42. Donhuijsen K, Sastry M, Volker B, Leder LD. 1992. Mast cell frequency in soft tissue tumors: relation to type and grade of malignancy. Pathol Res Pract 188:61-66.
43. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. 1992. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7:1471-1480.
44. Duncan LM, Richards LA, Mihm MC Jr. 1998. Increased mast cell density in invasive melanoma. J Cutan Pathol 25:11-15.
45. Dvorak HN, Senger DR, Dvorak AM, Harvey VS, McDonagh J. 1985. Regulation of extravascular coagulation by microvascular permeability. Science 227:1059-1061.
46. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK. 1987. Transforming growth factor b modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6:1899-1904.
47. Ezekowitz RA, Mulliken JB, Folkman J. 1992. Interferon-2 therapy for life-threatening hemangiomas of infancy. N Engl J Med 324:1456-1463.
48. Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, Caughey GH. 1999. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-β. J Immunol 162:5528-5535.
49. Ferrara N, Clapp C, Weiner R. 1991. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129:896-900.
50. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. 1997. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15:669-676.
51. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. 1994. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162:499-510.
52. Folkman J, Cotran R. 1976. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol 16:207.
53. Folkman, J., K. Whatson, D. Ingber, and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
54. Fong KM, Kida Y, Zimmerman PV, Smith PJ. 1996. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2:1369-1372.
55. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. 1997. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3:861-865.
56. Fontanini G, Boldrini L, Chine S, Pisaturo F, Basolo F, Calcinai A, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. 1999. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79:363-369.
57. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. 1995. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image. J Pathol 177:275-283.
58. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, White-house RM, Bicknell R, Gatter KC, Harris AL.1996. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73:275-280.
59. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. 1995. Regulation of vascular endothelial growth factor expression in cultured keratinocytes: implications for normal and impaired wound healing. J Biol Chem 270:12607-12613.
60. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 1995. Definition of two angiogenic pathways by distinct a v integrins. Science 270:1500-1502.
61. Friesel R., Komoriya A., Maciag T. 1987. Inhibition of endothelial cell proliferation by γ-interferon. J Cell Biol 104:689-696.
62. Furukawa T, Yshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y. 1992. Angiogenic factor. Nature (Lond) 356:668.
63. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM. 1997. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 73:812-815.
64. Goad DL, Rubin J, Wang H, Tashjian AH Jr, Patterson C. 1996. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262-2268.
65. Gooch JL, Lee AV, Yee D. 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58:4199-4205.
66. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624-6628.
67. Goto F, Goto K, Weindel K, Folkman J. 1993. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 69:508-517.
68. Grevin D, Chen JH, Raes MB, Stehelin D, Vandenbunder B, Desbiens X. 1993. Involvement of the proto-oncogene c-ets 1 and the urokinase plasminogen activator during mouse implantation and placentation. Int J Dev Biol 37:519-529.
69. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, Ramamurthy NS. 1989. Synovial procollegenase activation by human mast cell trytase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 84:1657-1662.
70. Gruber BL, Marchese MJ, Kew R. 1995. Angiogenic factors stimulate mast-cell migration. Blood 86:2488-2493.
71. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. 1995. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270:25915-25919.
72. Gualandris A, Urbinati C, Rusnati M, Ziche M, Presta M. 1994. Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. J Cell Physiol 161:149-159.
73. Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A, Bonsignore G. 1999. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol 30:788-794.
74. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF. 1995. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87:1237-1245.
75. Hamada H, Vallyathan V, Cool CD, Barker E, Inoue Y, Newman LS. 2000. Mast cell basic fibroblast growth factor in silicosis. Am J Respir Crit Care Med 161:2026-2034.
76. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
77. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. 1993. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochem J 296:803-809.
78. Haraguchi M, Kazutaka M, Uemura K, Sumizawa T. 1994. Angiogenic activity of enzymes. Nature (Lond) 368:198-200.
79. Hartveit F, Thoresen S, Tangen M, Maartmann-Moe H. 1984. Mast cell changes and tumour dissemination in human breast carcinoma. Invas Metast 4:146-155.
80. Hatanaka H, Abe Y, Naruke M, Tokunaga T, Oshika Y, Kawakami T, Osada H, Nagata J, Kamochi J, Tsuchida T, Kijima H, Yamazaki H, Inoue H, Ueyama Y, Nakamura M. 2001. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res 7:1287-1292.
81. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Weigand SJ. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998.
82. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. 1995. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41.
83. Hood JD, Meininger CJ, Ziche M, Granger HJ. 1998. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054-1058.
84. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
85. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. 1995. A biochemical characterization of the binding of osteopontin to integrins αvβ1 and αvβ5. J Biol Chem 270:26232-26238.
86. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M. 1999. Elevated levels of circulating plasma matrix metalloproteinase 9 in non small cell lung cancer patients. Clin Cancer Res 5:149-153.
87. Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M, Hirokawa K, Okada S, Hatano M, Tokuhisa T, Uede T. 1998. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest 78:1523-1533.
88. Imada A, Shijubo N, Kojima H, Abe S. 2000. Mast cell correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15:1087-1093.
89. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH. 1989. Identification of angiogenic activity and the cloning and expression of platelet endothelial growth factor. Nature (Lond) 338:556-562.
90. Jager R, Noll K, Havemann K, Pfluger KH, Knabbe C, Rauvala H, Zugmaier G. 1997. Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer 73:537-543.
91. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. 1994. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194-202.
92. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:1751.
93. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. 1998. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82:1359-1366.
94. Katagiri YU, Sleeman J, Fujii H, Herrlich H, Hotta K, Tanaka S, Chikuma H, Yagita k, Okumura M, Murakami I, Saiki AF, Chambers AF, Uede T. 1999. CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59:219-226.
95. Kankkunen JP, Harvima IT, Naukkarinen A. 1997. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 72:385-388.
96. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. 1994. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9:963-969.
97. Kerr LD, Miller DB, Matrisian LM. 1990. TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 61:267-278.
98. Kim I, Moon S-O, Kim SH, Kim HJ, Koh YS, Koh GY. 2001a. VEGF stimulates expression of ICAM-1, VCAM-1 and E-selectin through nuclear factor-B activation in endothelial cells. J Biol Chem 276:7614-7620.
99. Kim I, Moon SO, Park SK, Chae SW, Koh GY. 2001b. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89:477-479.
100. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. 1993. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 4:973-982.
101. Koblizek TL, Weiss C, Yancopoulos GD, Deutsch U, Risau W. 1998. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 8:529-532.
102. Kojima H, Shijubo N, Abe S. 2002. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer 94:1083-1093.
103. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T. 2000. Antibodies to different peptides in osteopontin reveal compexities in the various secreted forms. J Cell Biochem 77:487-98.
104. Koomagi R, Volm M.1998. Tissue-factor expression in human nonsmall-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 79:19-22.
105. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, White-house RM, Talbot DC, et al. 1997. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477-481.
106. Koukourakis MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J, Gatter KC, Harris AL. 1998. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer 77:1696-1703.
107. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL. 2000. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088-3095.
108. Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M. 1995. Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum 38:290-293.
109. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST. 1998. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55:29-42.
110. Lampugnani MG, Dejana E. 1997. Interendothelial junctions: structure, signaling and functional roles. Curr Opin Cell Biol 9:674-682.
111. Lauren J, Gunji Y, Alitalo K. 1998. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Path 153:1333-1339.
112. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI. 1996. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93:1988-1992.
113. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629.
114. Levy AP, Levy NS, Wegner S, Goldberg MA. 1995. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270:13333-13340.
115. Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, Patterson C, Endege WO, Zhou F, Lee ME. 1995. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem 270:308-312.
116. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. 1995. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95:713-724.
117. Luscinskas FW, Lawler J. 1994. Integrins as dynamic regulators of vascular function. FASEB J 8:929-938.
118. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Onoda N, Kato Y, Sowa M. 1996. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 73:884-888.
119. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. 1991. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271.
120. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. 1990. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77-79.
121. Maisonpierre PC, Goldfarb M, Yancopoulos GD, Gao G. 1993. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene 8:1631-1637.
122. Malone DG, Irani AM, Schwartz LB, Barrett KE, Metcalfe DD. 1986. Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum 29:956-963.
123. Matsumoto K, Ohi H, Kanmatsuse K. 1997. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 77:212-218.
124. Matsumura M, Chiba Y, Lu C, Amaya H, Shimomatsuya T, Horiuchi T, Muraoka R, Tanigawa N. 1998. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett 128:55-63
125. Mattern J, Koomagi R, Volm M. 1996. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73:931-934.
126. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM. 1997. Immunohistochemical analysis of integrin alphavbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 7:320-324.
127. McCulloch P, Choy A, Martin L 1995. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334-1335.
128. Metcalfe DD, Baram D, Mekori YA. 1997. Mast cells. Physiol Rev 77:1033-1079.
129. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha HJ, Dehio C. 1999. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363-374.
130. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. 1989. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 108:671-682.
131. Mignatti P, Mazzieri R, Rifkin DB. 1991. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 113:1193-1201.
132. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S. 1995. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55:1687-1690.
133. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, Zambonin-Zallone A, Ross FP, Teitelbaum SL, Cheresh D, et al. 1991. Recognition of osteopontin and related peptides by an αvβ3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 266:20369-20374.
134. Moghaddam A. 1995. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:988-1002.
135. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L 1986. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 83:7297-7301.
136. Mori J, Haisa M, Naomoto Y, Takaoka M, Kimura M, Yamatsuji T, Notohara K, Tanaka N. 2000. Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470. Jpn J Cancer Res 91:643-650
137. Muramatsu M, Katada J, Hayashi I, Majima M. 2000. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 275:5545-5552.
138. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. 1993. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157:351-358.
139. Naot D, Sionov RV, Ish-Shalom D. 1997. CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241-319
140. Nasu K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. 1995. Expression of wild-type and mutated rabbit osteopontin in Escherichia coli, and their effects on adhesion and migration of P388D1 cells. Biochem J 307:257-265.
141. Navarro P, Ruco L, Dejana E. 1998. Differential localization of VE-and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J. Cell Biol 140:1475-1484.
142. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22.
143. Nguyen M, Strubel NA, Bischoff J. 1993. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365:267-269.
144. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL. 2000. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82:1427-1432.
145. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J. 2001. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 91:1500-1509.
146. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. 1998. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273-31282.
147. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, Watanabe Y, Sasaki T. 1996. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2:1411-1416.
148. Ohta Y, Watanabe Y, Murakami S, Oda M, Hayashi Y, Nonomura A, Endo Y, Sasaki T. 1997. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 76:1041-1045.
149. Oka T, Ishida T, Nishino T, Sugimachi K. 1991. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 51:3522-3525.
150. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. 1996. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576-2581.
151. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S.1994. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280.
152. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328.
153. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
154. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. 1996. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 93:11675-11680.
155. Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H,
156. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, Pantel K. 2000. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 6:3944-3948.
157. Pauly JL, Schuller MG, Zelcer AA, Kris TA, Gore SS. 1997. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J Natl Cancer Inst 58:1587-1590.
158. Pepper MS, Ferrara N, Orci L, Montesano R. 1992. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-31.
159. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. 1994. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269:6271-6274.
160. Petrova TV, Makinen T, Alitalo K. 1999. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253:117-130.
161. Philip S, Bulbule A, Kundu GC. 2001. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276:44926-44935.
162. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. 1995. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580.
163. Rahimi N, Kazlauskas A. 1999. A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. Mol Biol Cell 10:3401-3407.
164. Ribatti D, Vacca A, Dammacco F. 1999. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1:293-302.
165. Rudzki Z, Jothy S. 1997. CD44 and the adhesion of neoplastic cells. Mol Pathol 50:57-71.
166. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M. 1996. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: possible roles of SP-1. J Biol Chem 271:28220-28228.
167. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. 1994. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 37:921-926.
168. Salomon D, Sacco PA, Roy SG, Simcha I, Johnson KR, Wheelock MJ, Ben-Ze'ev A. 1992. Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J Cell Biol 102:7-17.
169. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A, Frackelton AR Jr. 1993. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 142:1119-1130.
170. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. 1998. NF-κB mediates avb3 integrin-induced endothelial cell survival. J Cell Biol 141:1083-1093.
171. Schnurch H., Risau W. 1993. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial lineage. Development (Camb) 119:957-968.
172. Schor AM, Pazouki S, Morris J, Smither RL, Chandrachud LM, Pendleton N. 1998. Heterogeneity in microvascular density in lung tumours: comparison with normal bronchus. Br J Cancer 77:946-951.
173. Senger DR. 1996. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol 149:1-7.
174. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. 1988. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 48:5770-5774.
175. Senger DR, Perruzzi CA, Papadopoulos A. 1989. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1299.
176. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. 1994. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5:565-574.
177. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. 1997. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins. Proc Natl Acad Sci USA 94:13612-13617.
178. Shibusa T, Shijubo N, Abe S. 1998. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4:1483-1487.
179. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S. 1999. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160:1269-1273.
180. Shijubo N, Uede T, Kon S, Nagata M, Abe S. 2000. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncol 11:135-146.
181. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ. 1998. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66:1915-1918.
182. Sikora J, Slodkowska J, Radomyski A, Giedronowicz D, Kobos J, Kupis W, Rudzinski P. 1997. Immunohistochemical evaluation of tumour angiogenesis in adenocarcinoma and squamous cell carcinoma of lung. Rocz Akad Med Bialymst 42 S1:271-9.
183. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. 1990. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 171:1931-1942.
184. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF. 1997. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605-611.
185. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R, Giachelli CM. 1996. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by a9b1 integrin. J Biol Chem 271:28485-28491.
186. Smith LL, Giachelli CM. 1998. Structural requirements for α9β1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res 242:351-360.
187. Smith LL, Greenfield BW, Aruffo A. 1999. CD44 is not an adhesive receptor for osteopontin. J Cell Biochem 73:20-30
188. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. 1999. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18:882-892.
189. Starkey JR, Crowle PK, Taubenberger S. 1988. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 42:48-52.
190. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. 1995 Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 92:11-14.
191. Stratmann A, Risau W, Plate KH. 1998. Cell-type specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466.
192. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. 1995. Interferon-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Comm 210:51-57.
193. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180.
194. Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi S, Kotake Y, Konishi Y. 1999. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 5:2506-2510.
195. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, Kodaira S. 1996. Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. Jpn J Clin Oncol 26:293-297.
196. Takanami I, Tanaka F, Hashizume T, Kodaira S. 1997. Tumor angiogenesis in pulmonary adenocarcinomas: relationship with basic fibroblast growth factor, its receptor, and survival. Neoplasma 44:295-298.
197. Takanami I, Takeuchi K, Naruke M. 2000. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686-2692.
198. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T. 1996. Clinicopathologic and prognostic significance of angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Nat Cancer Ins 88:1110-1117.
199. Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K, Hayakawa T. 1990. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun 171:1264-1271.
200. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M. 1996. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 56:2671-2676.
201. Teti A, Farina AR, Villanova I, Tiberio A, Tacconelli A, Sciortino G, Chambers AF, Gulino A, Mackay AR. 1998. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer 77:82-93.
202. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW. 1999. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271-2277.
203. Toi M, Kashitani J, Tominaga T. 1993. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374.
204. Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M, Tominaga T. 1999. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 5:1131-1137.
205. Tolnay E, Wiethege T, Kuhnen C, Wulf M, Voss B, Muller KM. 1997. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer. J Cancer Res Clin Oncol 123:652-658.
206. Tomita M, Matsuzaki Y, Onitsuka T. 2000. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg 69:1686-1690.
207. Trabucchi E, Radaelli E, Marazzi M, Foschi D, Musazzi M, Veronesi AM, Montorsi W. 1988. The role of mast cells in wound healing. Int J Tissue React 10:367-372.
208. Tsai JC, Goldman CK, Gillespie GY. 1995. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82:864-783.
209. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. 1998. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502-508.
210. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF. 1999. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246.
211. Ue T, Okozaki H, Kitadai Yamamoto YS, Yasui W, Ishikawa T, Tahara E. 1998. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 9:127-132.
212. Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, Heldin CH. 1992. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 184:1311-1316.
213. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. 1996. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474-2484.
214. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z. 1991. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 16:268-271.
215. Volm M, Koomagi R, Mattern J, Stammler G. 1997. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 33:691-693.
216. Volm M, Mattern J, Koomagi R. 1998. Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. Int J Oncol 13:975-979.
217. Volm M, Mattern J, Koomagi R. 1999. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol Rep 6:611-615.
218. Weber GF, Ashkar S, Glimcher MJ, Cantor H. 1996. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509-512.
219. Weber GF, Cantor H. 1996. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 7:241-248.
220. Weich HA, Iberg N, Klagsbrun M, Folkman J. 1991. Transcriptional regulation of basic fibroblast growth factor gene expression in capillary endothelial cells. J Cell Biochem 47:158-164.
221. Weidner N, Semple JP, Welch WR, Folkman J. 1991. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
222. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. 1993. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409.
223. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. 1994. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504-6511.
224. Weiss JM, Renkl AC, Maier CS, Kimmig M, Liaw L, Ahrens T, Kon S, Maeda M, Hotta H, Uede T, Simon JC. 2001. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 194:1219-1229.
225. White ES, Strom SR, Wys NL, Arenberg DA. 2001a. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 166:7549-7555.
226. White ES, Livant DL, Markwart S, Arenberg DA.2001b Monocyte-Fibronectin Interactions, via a5b1 integrin, induce xxpression of CXC chemokine-dependent angiogenic activity. J Immunol 167:5362-5366.
227. Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K, Stacker SA. 1999. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 96:3071-3076.
228. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. 1998. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie 2. J Biol Chem 273:18514-18521
229. Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, Chung LP. 2000. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29:11-22.
230. Yamamoto T, Katayama I, Nishioka K, Duncan LM, Richards LA, Mihm MC Jr. 1997. Expression of stem cell factor in basal cell carcinoma. Br J Dermatol 137:709-713.
231. Yap AS, Brieher WM, Gumbiner BM. 1997. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol 13:119-146
232. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A. 2001. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633-1637.
233. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D. 1999. The integrin α9β1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274:36328-36334.
234. Yuan A, Yang PC, Yu CJ, Lee YC, Yao YT, Chen CL, Lee LN, Kuo SH, Luh KT. 1995. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 152:2157-2162.
235. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. 1994. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320-1327.